Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis * Text only * * Home * Journals * * Other NIHR research * * For authors * For reviewers * About * Policies * * Accessibility * Journals
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma Technology appraisal guidance Published: 29 August 2024 www.nice.org.uk in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pembrolizumab
Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Pembrolizumab (Adenokarzinom des Magens oder des gastroösophagealen Übergangs, HER2-positiv) – Nutzenbewertung gemäß § 35a SGB V. Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive) Benefit assessment according to §35a SGB V1 EXTRACT Project: A24-01 Version: 1.0 Status: 26 Mar 2024 DOI: 10.60584/A24-01_en Extract of dossier assessment
Pembrolizumab (gastric cancer, HER2-negative) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Pembrolizumab (Adenokarzinom des Magens oder des gastroösophagealen Übergangs, HER2-negativ) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However , solely the German original text is absolutely authoritative and legally binding. Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-negative) Benefit assessment according to §35a SGB V1 EXTRACT Project: A24-02 Version: 1.0 Status: 27 Mar 2024 DOI: 10.60584/A24-02_en Extract of dossier assessment A24-02 Version 1.0 Pembrolizumab ( gastric or gastro-oesophageal junction
Pembrolizumab (biliary cancer) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Pembrolizumab (biliäres Karzinom) – Nutzenbewertung gemäß § 35a SGB V. Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Pembrolizumab (biliary carcinoma) Benefit assessment according to §35a SGB V1 EXTRACT Project: A24-03 Version: 1.0 Status: 27 Mar 2024 DOI: 10.60584/A24-03_en Extract of dossier assessment A24-03 Version 1.0 Pembrolizumab ( biliary carcinoma) 27 Mar 2024 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute
Pembrolizumab (NSCLC, neoadjuvant + adjuvant) ' Addendum to Project A24-46 1 Translation of the addendum Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Addendum zum Projekt A24-46 (Dossierbewertung). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Pembrolizumab (NSCLC, neoadjuvant + adjuvant) Addendum to Project A24-46 (dossier assessment)1 ADDENDUM Project: A24-93 Version: 1.0 Status: 25 Sep 2024 DOI: 10.60584/A24-93_en Addendum A24-93 Version 1.0 Pembrolizumab – Addendum to Project A24-46 25 Sep 2024 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic